Concierge Medicine: What Quality of Earnings Reveals Before You Invest
Forward Health raised roughly USD 650 million, reached a USD 1 billion valuation, and shut down almost overnight. In membership healthcare, funding and sign-ups are not the same as durable, recognised earnings — and that distinction is the whole game for any investor or acquirer in the sector.
Forward Health raised roughly USD 650 million, reached a USD 1 billion valuation, and built tech-enabled clinics across major US cities. It generated less than USD 100 million in total revenue over eight years, and in November 2024 it shut down almost overnight (Maginative; ICT&health, 2024). Forward sold the same core promise concierge medicine is built on: premium subscription-based access to a doctor. Its collapse is a reminder that in membership healthcare, funding and sign-ups are not the same as durable, recognised earnings. For any investor or acquirer in the sector, that distinction is the whole game.
Why the Sector Is Attracting Capital Now
The category is expanding quickly. The US concierge medicine market was valued at USD 7.35 billion in 2024 and is forecast to grow at a 10.33% CAGR to USD 13.23 billion by 2030, according to Grand View Research (2025). Capital has followed: private equity backs the larger platforms, and Amazon acquired One Medical for roughly USD 3.9 billion in 2023 (Fierce Healthcare, 2023). The drivers are structural: physician burnout, long wait times, an aging population, and rising willingness among higher-income patients and employers to pay for access. Rising valuations, combined with the accounting quirks of upfront membership fees, make earnings quality the variable that decides whether a deal is sound or a write-down in waiting.
Deferred Revenue Sits at the Heart of the Model
Members typically pay an annual fee upfront, often USD 2,000 to USD 5,000, with premium plans exceeding USD 10,000. Under ASC 606, that cash cannot be booked as revenue on day one. The fee is recorded as deferred revenue, a contract liability, and recognised ratably as care is delivered. This creates large deferred-revenue balances and a structural gap between cash collected and revenue earned. A business that recognises upfront fees faster than it delivers service reports stronger current revenue and thinner future revenue than reality supports. What this means: confirm that recognition tracks the service period, and reconcile the deferred-revenue roll-forward against cash collections and membership counts.
Retention Is the Entire Investment Thesis
A membership business is only a recurring-revenue business if members renew. Retention, not sign-ups, determines the durability of the earnings a buyer is acquiring. The metrics that matter are member retention, churn, average revenue per member, and members per physician panel. Growth bought through discounting is the warning sign. After acquiring One Medical, Amazon cut first-year membership pricing to USD 144 from the standard USD 199 to drive sign-ups (Fierce Healthcare, 2023). One Medical itself grew 2022 revenue to USD 1.05 billion, up 68%, while posting a net loss of roughly USD 398 million (One Medical FY2022 results). Scale did not equal profitability. What this means: test renewal cohorts at standard pricing, not gross sign-ups, and separate durable members from promotional ones.
Business Model Dictates the Earnings Profile
Concierge medicine is not one model. Independent physician-owned practices are small and asset-light. Management platforms supply technology, billing, and patient acquisition across many affiliated physicians; MDVIP, the largest US network, affiliates well over a thousand. Employer-sponsored models sell per-member-per-month access as a corporate benefit. Vertically integrated operators own the clinics, employ the physicians, and carry the full cost base: higher fixed costs, depreciation, lease expense, and mixed subscription and fee-for-service recognition. Forward and Sollis Health sit at this capital-heavy end. The error buyers make is pricing a capital-intensive integrated operator as if it were an asset-light platform. What this means: the multiple and the QoE scope must match the structure, not the sector label.
Six Red Flags in a Concierge Medicine QoE
• Revenue recognised ahead of service. Upfront annual fees booked faster than care is delivered overstate current revenue and understate the deferred-revenue liability. Confirm ratable recognition against the membership period. • Growth driven by discounts, not renewals. Member counts inflated by promotional pricing do not prove durable demand. Amazon's USD 144 first-year One Medical pricing shows how headline membership growth can be price-bought (Fierce Healthcare, 2023). • Capital intensity hidden behind a subscription story. A membership label does not make a clinic-heavy operator asset-light. Forward pitched subscription access while carrying the cost of tech-enabled clinics and CarePod kiosks, and burned through roughly USD 650 million before closing in 2024 (ICT&health, 2024). • Physician concentration and unsustainable compensation. Reliance on a few high-volume physicians, or above-market pay to retain them, threatens both revenue and margin if they leave. Test concentration and benchmark compensation. • EBITDA add-backs that never end. Recurring "expansion," "recruiting," and "technology" costs added back as one-time items inflate normalised EBITDA. Scrutinise whether each add-back is genuinely non-recurring. • Refund liabilities and related-party arrangements. Cancellation policies create real liabilities on early termination, and physician-ownership or management agreements can obscure related-party economics. Both deserve forensic review.
How MARC Adds Value
MARC applies institutional-grade Quality of Earnings analysis to subscription healthcare businesses, where the gap between cash collected and revenue earned is wide and easy to misread. • Deferred-revenue and revenue-recognition testing that reconciles upfront collections to the service period and to membership counts. • Retention and cohort analysis that separates durable members from discount-driven sign-ups. • EBITDA normalisation that challenges add-backs for expansion, recruiting, and technology. • Sector benchmarking that prices each target to its actual business model, not the headline category. In a market drawing capital at a double-digit growth rate, that discipline is the difference between a defensible valuation and an impairment.
FAQs
What is concierge medicine? A membership-based care model where patients pay a recurring fee, typically USD 2,000 to USD 5,000 a year, for enhanced access such as same-day appointments, longer consultations, and 24/7 physician availability. It complements rather than replaces traditional insurance, which still covers hospitalisation and catastrophic costs. Why does deferred revenue matter in concierge medicine? Members pay annual fees upfront, but service is delivered over twelve months. Under ASC 606, the fee is booked as deferred revenue and recognised gradually as care is provided, so recognition timing is one of the most important things to verify in diligence. How do investors assess a concierge medicine business? The priority areas are revenue-recognition timing, member retention and churn, average revenue per member, physician concentration and compensation, EBITDA add-backs, and the cost structure implied by the business model. Durable renewals at standard pricing matter far more than gross sign-ups. How large is the concierge medicine market? The US market was valued at about USD 7.35 billion in 2024 and is forecast to reach USD 13.23 billion by 2030 at a 10.33% CAGR, according to Grand View Research (2025). Growth is driven by physician shortages, long wait times, and rising demand for preventive, personalised care.
Key Takeaway
The future of concierge medicine belongs to investors who underwrite membership durability and recognition integrity, not sign-up velocity. The buyers who interrogate deferred revenue, retention, and cost structure will price deals to economic reality. Those who pay an asset-light subscription multiple for a capital-heavy or discount-driven business will learn the lesson Forward's backers did. In membership healthcare, the quality of earnings, not the speed of growth, decides who wins. Let MARC power your next diligence move.
About MARC Analytics Team
Our research team comprises experienced financial analysts and consultants with over 50+ years of combined experience.
View all articles →Test Earnings Quality Before You Close
Let MARC power your next diligence move in subscription healthcare.
